Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 271
- 试验地点
- 1
- 主要终点
- We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
研究概览
简要总结
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
详细描述
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision.
The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool.
The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of pancreatic ductal adenocarcinoma
- •Signed initial informed consent
- •Participant agrees to genetic counseling
排除标准
- •Prospective participant unable to sign informed consent based on referring physician recommendation.
- •Patient has neuroendocrine pancreatic tumor
结局指标
主要结局
We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool
时间窗: Up to 5 years
次要结局
- Evaluate Patient Experience With Genetic Testing(up to 5 years)
- Summarize patient satisfaction with Genetic counseling(up to 5 years)
- Number of patients who disclose genetic testing results to relatives(up to 5 years)
研究者
Matthew B. Yurgelun, MD
Matthew B. Yurgelun, MD
Dana-Farber Cancer Institute